Status: Not yet recruiting
Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients
An Exploratory Study on the Efficacy and Safety of Different Administration Routes of SHR-A1811 in the Treatment of HER2-Positive Advanced Breast Cancer
Participants needed: 60
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Tianjin Medical University Cancer Institute and HospitalUpdated: Jun 11, 2026Locations: 1
Eligibility criteria
Aged ≥ 18 years old. [+6]
Prior treatment with anti-HER2 antibody-drug conjugates (ADC). [+13]